Amgen (NASDAQ:AMGN) — This independent biotech company has been a leader in the development of genetically based research and treatment for cancer, anemia, rheumatoid arthritis and a host of other major illnesses.
The stock jumped on Friday when Goldman Sachs removed it from its �sell� list and moved it to �neutral,� based on the retirement of its CEO and head of research. S&P has a �four-star buy� on Amgen.
Technically Friday�s action broke AMGN from the first-stage, cup-and-handle base. Buy on a breakout of its former high at $61.50 or a pullback to Thursday�s high at $59.06, the bottom of a breakaway gap. The target for AMGN is $68 to $70.
Click to Enlarge�
No comments:
Post a Comment